Enterprise Trust & Investment’s AbbVie ABBV Stock Holding History

Enterprise Trust & Investment’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$19K	Buy	+125	New	+$19.1K	0.01%	176

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Enterprise Trust & Investment's ABBV Position: Q2 2022 in Review

Enterprise Trust & Investment opened a new position in AbbVie (ABBV) in Q2 2022: 125 shares worth $19K. The stake represents 0.01% of the portfolio and ranks #176 among its holdings.

3,004 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

Enterprise Trust & Investment held 125 shares of AbbVie worth $19K as of Q2 2022.
AbbVie was a new Enterprise Trust & Investment position in Q2 2022.
AbbVie made up 0.01% of Enterprise Trust & Investment's portfolio in Q2 2022, its #176 holding.
3,004 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Enterprise Trust & Investment's 13F filing for Q2 2022, filed 22 Jul 2022.